mardi 12 juin 2018

Onco Actu du 12 juin 2018

1.4 Biologie - Technos

Gene editing stocks get bushwhacked as new studies highlight CRISPR/Cas9 cancer risks [EndPoints]

Gene editing tool may raise cancer risk in cells, scientists warn [Reuters]

A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies [STAT]

4.1 Dép., diag. & prono. - Prostate

Testing for 63 gene variants identifies elevated risk for prostate cancer [FierceBiotech]

Men left in danger because they do not know prostate cancer runs in families [The Telegraph]

Trials begin of a saliva test for prostate cancer [The Guardian]

Prostate cancer DNA test identifies men with six-fold increased risk [Institute of Cancer Research]

4.12 Biopsies liquides

Pathologists predicted the Theranos debacle, but their voices were missing from most news coverage [HealthNewsReview]

4.2 Dép., diag. & prono. - Génome

A Science Writer Explores The 'Perversions And Potential' Of Genetic Tests [NPR]

5.1 Traitements - Pré-clinique

A faster way to spot the tell-tale signs of cancer-causing drugs [European Commission]

5.12 Immunothérapies

Metastatic Breast Cancer and the Apparent Triumph of Immunotherapy: Thoughts from a Patient [Katherine O'Brien]

5.12.7 Immunothérapies - vaccins

Cancer Research UK tests first of its kind vaccine to treat lung cancer [Cancer Research UK]

5.2 Pharma

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label [Amgen]

5.2.3 Pharma - économie

After cash funneling scandal, biotech billionaire Soon-Shiong charges on with Nant IPO [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia [Roche]

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia [EndPoints]

5.4 Traitements - Economie

Easier Drug Approval Isn’t Cutting Drug Prices [NY Times]

5.5 ASCO

Maximizing the Prospects for Progress Against Cancer [NCI]

Sharpless: NCI adds $10 million for NCTN and NCORP trials [The Cancer Letter] ASCO (médecine de précision-sein)

Big takeaway from ASCO: 70 percent of women with early breast cancer don’t benefit from adjuvant chemotherapy [The Cancer Letter]

6. Lutte contre les cancers

Sam Finnikin: NICE move to improve the quality of shared decision making [BMJ Blogs]

6.6 Publications

North American Universities Increasingly Cancel Publisher Packages [The Scientist]

China introduces sweeping reforms to crack down on academic misconduct [Nature]